Dr. Reddy’s Laboratories (RDY) to Release Quarterly Earnings on Thursday

Dr. Reddy’s Laboratories (NYSE:RDY) is expected to release its Q3 25/26 results before the market opens on Thursday, January 22nd. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.16 per share and revenue of $963.8440 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 25/26 earning overview page for the latest details on the call scheduled for Wednesday, January 21, 2026 at 9:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Friday, October 24th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.14% and a return on equity of 17.13%. The firm had revenue of $993.72 million during the quarter, compared to the consensus estimate of $944.26 million. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Trading Up 0.1%

Shares of RDY stock opened at $12.93 on Wednesday. The company has a quick ratio of 1.35, a current ratio of 1.85 and a debt-to-equity ratio of 0.03. The firm has a market cap of $10.80 billion, a P/E ratio of 15.97, a PEG ratio of 6.36 and a beta of 0.37. The company has a 50 day moving average of $13.85 and a 200-day moving average of $14.11. Dr. Reddy’s Laboratories has a 12-month low of $12.26 and a 12-month high of $16.17.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RDY. Invesco Ltd. lifted its position in shares of Dr. Reddy’s Laboratories by 7.6% during the second quarter. Invesco Ltd. now owns 253,342 shares of the company’s stock worth $3,808,000 after acquiring an additional 17,907 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Dr. Reddy’s Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after purchasing an additional 1,294 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Dr. Reddy’s Laboratories by 23.3% during the 2nd quarter. First Trust Advisors LP now owns 65,652 shares of the company’s stock valued at $987,000 after purchasing an additional 12,390 shares during the period. Sei Investments Co. lifted its holdings in Dr. Reddy’s Laboratories by 37.3% during the 2nd quarter. Sei Investments Co. now owns 124,136 shares of the company’s stock worth $1,866,000 after purchasing an additional 33,747 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Dr. Reddy’s Laboratories by 92.6% in the 2nd quarter. Quantinno Capital Management LP now owns 235,044 shares of the company’s stock worth $3,533,000 after purchasing an additional 112,988 shares during the period. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Dr. Reddy’s Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $16.90.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.